Remitly has achieved operational profitability, but the stock has underperformed due to market concerns over its share dilution. Despite impressive revenue growth outpacing peers, Remitly’s stock ...

I give Niagen Bioscience, Inc. a hold rating. The company has a cash-rich balance sheet with no debt and high-quality earnings. Shareholders have already faced 47.5% dilution since 2016, and there ...